NEUROONE MEDICAL TECHNOLOGIES Corp Cash Flow Statement
NMTC|10 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
NEUROONE MEDICAL TECHNOLOGIES Corp used $11M in operating cash flow and negative free cash flow of $11M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2016 | FY2015 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$12.3M | -$11.9M | -$10.0M | -$9.9M | -$13.6M | -$62.9K | -$36.2K | -$30.6K | -$27.6K | -$6.0K |
| Depreciation & Amortization | $246.8K | $199.3K | $118.6K | $80.7K | $47.6K | - | - | - | - | - |
| Operating Cash Flow | -$11.0M | -$12.9M | -$7.5M | -$8.6M | -$3.4M | -$30.2K | -$26.2K | -$25.1K | -$27.4K | -$5.1K |
| Capital Expenditures | $120.2K | $384.1K | $275.2K | $67.1K | $122.4K | - | - | - | - | - |
| Free Cash Flow | -$11.1M | -$13.3M | -$7.8M | -$8.7M | -$3.5M | - | - | - | - | - |
| FCF Margin | -322.4% | -679.7% | -4553.8% | -4866.7% | -1991.5% | - | - | - | - | - |